Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "ZINPLAVA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides a detailed picture of the ZINPLAVA for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZINPLAVA for clostridium difficile infection.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZINPLAVA market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.
Drug Summary
ZINPLAVA (bezlotoxumab), developed by Merck Sharp & Dohme LLC (MSD) is a human monoclonal antibody that binds to C. difficile Toxin B, indicated to reduce the recurrence of CDI in patients 18 years or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence. In vitro studies in cell-based assays using Vero cells or Caco-2 cells suggest that the drug neutralizes the toxic effects of toxin B. ZINPLAVA is used in conjunction with antibacterial drug treatment of CDI.
The FDA approval of ZINPLAVA was based on two Phase III trials, MODIFY I and II. ZINPLAVA is not an antibacterial drug and is not indicated for the treatment of CDI (Merck, 2016a). In May 2022, Merck completed the Phase III trial (MODIFY III) for rCDI in children aged 1 to < 18 years of age with a confirmed diagnosis of CDI.
ZINPLAVA Analytical Perspective
In-depth ZINPLAVA Market Assessment
This report provides a detailed market assessment of ZINPLAVA for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
ZINPLAVA Clinical Assessment
The report provides the clinical trials information of ZINPLAVA for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZINPLAVA dominance.
- Other emerging products for clostridium difficile infection are expected to give tough market competition to ZINPLAVA and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZINPLAVA in clostridium difficile infection.
- This in-depth analysis of the forecasted sales data of ZINPLAVA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZINPLAVA in clostridium difficile infection.
Key Questions
- What is the product type, route of administration and mechanism of action of ZINPLAVA?
- What is the clinical trial status of the study related to ZINPLAVA in clostridium difficile infection and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZINPLAVA development?
- What are the key designations that have been granted to ZINPLAVA for clostridium difficile infection?
- What is the forecasted market scenario of ZINPLAVA for clostridium difficile infection?
- What are the forecasted sales of ZINPLAVA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What are the other emerging products available and how are these giving competition to ZINPLAVA for clostridium difficile infection?
- Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?
Key Topics Covered:
1. Report Introduction
2. ZINPLAVA Overview in Clostridium difficile infection
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestone
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. ZINPLAVA Market Assessment
5.1. Market Outlook of ZINPLAVA in Clostridium difficile infection
5.2. 7MM Analysis
5.2.1. Market Size of ZINPLAVA in the 7MM for Clostridium difficile infection
5.3. Country-wise Market Analysis
5.3.1. Market Size of ZINPLAVA in the United States for Clostridium difficile infection
5.3.2. Market Size of ZINPLAVA in Germany for Clostridium difficile infection
5.3.3. Market Size of ZINPLAVA in France for Clostridium difficile infection
5.3.4. Market Size of ZINPLAVA in Italy for Clostridium difficile infection
5.3.5. Market Size of ZINPLAVA in Spain for Clostridium difficile infection
5.3.6. Market Size of ZINPLAVA in the United Kingdom for Clostridium difficile infection
5.3.7. Market Size of ZINPLAVA in Japan for Clostridium difficile infection
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/5fhp51
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
